Armata Pharmaceuticals, Inc. — Earnings Release 2008

Aug 7, 2008

8-K 1 v122232_8k.htm Licensed to: vintage filings llc Document Created using EDGARizer HTML 3.0.4.0 Copyright 2006 EDGARfilings, Ltd., an IEC company. All rights reserved EDGARfilings.com

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) August 6, 2008

| Targeted
Genetics Corporation |
| --- |
| (Exact
name of registrant as specified in its
charter) |

Washington	0-23930	91-1549568
(State
or other jurisdiction of
incorporation)	(Commission
File Number)	(IRS
Employer Identification
No.)

| 1100
Olive Way, Suite 100, Seattle, Washington | 98101 |
| --- | --- |
| (Address
of principal executive offices) | (Zip
Code) |

Registrant's telephone number, including area code (206) 623-7612

| Not
Applicable |
| --- |
| (Former
name or former address if changed since last
report) |

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 2.02. Results of Operations and Financial Condition.

On August 6, 2008, Targeted Genetics Corporation announced financial results for the quarter ended June 30, 2008. A copy of the press release related to this announcement is attached as Exhibit 99.1 and is incorporated into this current report by reference.

Item 9.01. Financial Statements and Exhibits.

Exhibits.

99.1 Press Release of Targeted Genetics Corporation dated August 6, 2008

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

| /s/
David J. Poston |
| --- |
| David
J. Poston |
| Vice President Finance and |
| Chief Financial Officer |

INDEX TO EXHIBITS

Exhibit Number	Description
99.1	Press
Release of Targeted Genetics Corporation dated August 6,
2008